Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer

This study has been terminated.

(The study was terminated because Cell Genesys stopped all activities for GVAX.)

Sponsor:

Collaborators:

Cell Genesys

Medarex

Information provided by (Responsible Party):

A.J.M. van den Eertwegh, VU University Medical Center

ClinicalTrials.gov Identifier:

NCT01510288

First received: January 4, 2012

Last updated: January 10, 2012

Last verified: January 2012

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been terminated.
Study Completion Date:	November 2011
Primary Completion Date:	December 2007 (Final data collection date for primary outcome measure)

No publications provided by VU University Medical Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo HM, Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N, Gerritsen WR. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012 May;13(5):509-17. doi: 10.1016/S1470-2045(12)70007-4. Epub 2012 Feb 10.

To Top